Vaishali Pharma Limited (NSE:VAISHALI)
India
· Delayed Price · Currency is INR 6.51
-0.23 (-3.41%)
Mar 9, 2026, 3:28 PM IST
Vaishali Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,141 | 990.26 | 862.8 | 696.63 | 758.21 | 537.74 | Upgrade
|
| Other Revenue | 0 | 0 | - | - | - | - | Upgrade
|
| Revenue | 1,141 | 990.26 | 862.8 | 696.63 | 758.21 | 537.74 | Upgrade
|
| Revenue Growth (YoY) | 15.04% | 14.77% | 23.85% | -8.12% | 41.00% | -10.51% | Upgrade
|
| Cost of Revenue | 1,013 | 857.12 | 744.37 | 547 | 635.17 | 461.7 | Upgrade
|
| Gross Profit | 127.44 | 133.14 | 118.43 | 149.63 | 123.04 | 76.04 | Upgrade
|
| Selling, General & Admin | 33.27 | 30.29 | 28.11 | 26.1 | 22.13 | 19.39 | Upgrade
|
| Other Operating Expenses | 55.98 | 46.52 | 28.03 | 29.75 | 32.06 | 11.97 | Upgrade
|
| Operating Expenses | 150.32 | 137.11 | 112.13 | 60.89 | 58.75 | 53.83 | Upgrade
|
| Operating Income | -22.88 | -3.97 | 6.3 | 88.74 | 64.29 | 22.21 | Upgrade
|
| Interest Expense | -16.84 | -15.83 | -17.37 | -22.56 | -24.89 | -26.26 | Upgrade
|
| Interest & Investment Income | 26.06 | 26.06 | 13.92 | 12.55 | 12.98 | 12.58 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.18 | 3.18 | 1.71 | 5.41 | 4.43 | 3.98 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.53 | 2.82 | 4.7 | 4.33 | 0.47 | 1.52 | Upgrade
|
| EBT Excluding Unusual Items | -3.76 | 12.26 | 9.26 | 88.46 | 57.28 | 14.05 | Upgrade
|
| Pretax Income | -3.76 | 12.26 | 9.26 | 88.46 | 57.28 | 14.05 | Upgrade
|
| Income Tax Expense | 1.33 | 4.08 | 2.07 | 22.43 | 17.05 | 3.58 | Upgrade
|
| Net Income | -5.09 | 8.17 | 7.19 | 66.04 | 40.24 | 10.46 | Upgrade
|
| Net Income to Common | -5.09 | 8.17 | 7.19 | 66.04 | 40.24 | 10.46 | Upgrade
|
| Net Income Growth | - | 13.70% | -89.11% | 64.12% | 284.58% | 3091.34% | Upgrade
|
| Shares Outstanding (Basic) | 114 | 126 | 107 | 105 | 105 | 105 | Upgrade
|
| Shares Outstanding (Diluted) | 114 | 126 | 107 | 112 | 105 | 105 | Upgrade
|
| Shares Change (YoY) | -17.49% | 17.99% | -4.07% | 5.95% | - | - | Upgrade
|
| EPS (Basic) | -0.04 | 0.06 | 0.07 | 0.63 | 0.38 | 0.10 | Upgrade
|
| EPS (Diluted) | -0.05 | 0.06 | 0.07 | 0.59 | 0.38 | 0.10 | Upgrade
|
| EPS Growth | - | -10.54% | -88.65% | 54.90% | 284.58% | 3091.96% | Upgrade
|
| Free Cash Flow | - | -183.43 | 6.96 | 7.82 | 4.54 | 18.85 | Upgrade
|
| Free Cash Flow Per Share | - | -1.45 | 0.07 | 0.07 | 0.04 | 0.18 | Upgrade
|
| Gross Margin | 11.17% | 13.44% | 13.73% | 21.48% | 16.23% | 14.14% | Upgrade
|
| Operating Margin | -2.01% | -0.40% | 0.73% | 12.74% | 8.48% | 4.13% | Upgrade
|
| Profit Margin | -0.45% | 0.83% | 0.83% | 9.48% | 5.31% | 1.95% | Upgrade
|
| Free Cash Flow Margin | - | -18.52% | 0.81% | 1.12% | 0.60% | 3.51% | Upgrade
|
| EBITDA | -20.53 | -1.53 | 8.86 | 91.37 | 66.8 | 24.48 | Upgrade
|
| EBITDA Margin | -1.80% | -0.15% | 1.03% | 13.11% | 8.81% | 4.55% | Upgrade
|
| D&A For EBITDA | 2.35 | 2.45 | 2.57 | 2.63 | 2.51 | 2.26 | Upgrade
|
| EBIT | -22.88 | -3.97 | 6.3 | 88.74 | 64.29 | 22.21 | Upgrade
|
| EBIT Margin | -2.00% | -0.40% | 0.73% | 12.74% | 8.48% | 4.13% | Upgrade
|
| Effective Tax Rate | - | 33.32% | 22.37% | 25.35% | 29.76% | 25.51% | Upgrade
|
| Revenue as Reported | 1,177 | 1,022 | 883.13 | 718.92 | 776.09 | 555.83 | Upgrade
|
| Advertising Expenses | - | 4.48 | 4.86 | 5.29 | 0.86 | 0.66 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.